Cargando…

Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma

To overcome radioresistance in the treatment of osteosarcoma, a primary malignant tumor of the bone, radiotherapy is generally combined with radiosensitizers. The purpose of this study was to investigate a third-generation bisphosphonate, zoledronic acid (ZOL), as a radiosensitizer for osteosarcoma....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Eun Ho, Kim, Mi-Sook, Lee, Kyung-Hee, Koh, Jae-Soo, Jung, Won-Gyun, Kong, Chang-Bae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342595/ https://www.ncbi.nlm.nih.gov/pubmed/27765919 http://dx.doi.org/10.18632/oncotarget.12281

Ejemplares similares

Carbon-Ion Beam Irradiation Alone or in Combination with Zoledronic acid Effectively Kills Osteosarcoma Cells
por: Kim, Eun Ho, et al.
Publicado: (2020)

Effect of low- and high-linear energy transfer radiation on in vitro and orthotopic in vivo models of osteosarcoma by activation of caspase-3 and -9
por: Kim, Eun Ho, et al.
Publicado: (2017)

Synergistic Autophagy Effect of miR-212-3p in Zoledronic Acid-Treated In Vitro and Orthotopic In Vivo Models and in Patient-Derived Osteosarcoma Cells
por: Oh, Ju Yeon, et al.
Publicado: (2019)

Metformin enhances the radiosensitivity of human liver cancer cells to γ–rays and carbon ion beams
por: Kim, Eun Ho, et al.
Publicado: (2016)

Correction: Oh, J.Y., et al. Synergistic Autophagy Effect of miR-212-3p in Zoledronic Acid-Treated In Vitro and Orthotopic In Vivo Models and in Patient-Derived Osteosarcoma Cells, Cancers 2019, 11, 1812
por: Oh, Ju Yeon, et al.
Publicado: (2020)

Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells
por: Ory, B, et al.
Publicado: (2008)

Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?
por: Lee, Jun Ah, et al.
Publicado: (2012)

Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro
por: Fu, Dehao, et al.
Publicado: (2011)

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma
por: Lamoureux, Francois, et al.
Publicado: (2014)

Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients
por: Conry, Robert M., et al.
Publicado: (2016)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation
por: Chie, Eui Kyu, et al.
Publicado: (2015)

The Effect of Zoledronic Acid on the Volume of the Fusion-Mass in Lumbar Spinal Fusion
por: Park, Ye-Soo, et al.
Publicado: (2013)

Therapeutic Effects of Zoledronic Acid-Loaded Hyaluronic Acid/Polyethylene Glycol/Nano-Hydroxyapatite Nanoparticles on Osteosarcoma
por: Xu, Yan, et al.
Publicado: (2022)

Retrospective growth kinetics and radiosensitivity analysis of various human xenograft models
por: Lee, Ji Young, et al.
Publicado: (2016)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis
por: Kong, Li, et al.
Publicado: (2020)

Zoledronate‐Associated Osteonecrosis of the Jaw in a Dog with Appendicular Osteosarcoma
por: Lundberg, A.P., et al.
Publicado: (2016)

CHK2 is involved in the p53-independent radiosensitizing effects of valproic acid
por: Choo, Dong Wan, et al.
Publicado: (2017)

Zoledronic acid induces ferroptosis by reducing ubiquinone and promoting HMOX1 expression in osteosarcoma cells
por: Ren, Tianhao, et al.
Publicado: (2023)

Gold nanoparticles as a potent radiosensitizer in neutron therapy
por: Kim, Eun Ho, et al.
Publicado: (2017)

A successful treatment of hypercalcemia with zoledronic acid in a 15-year-old boy with acute lymphoblastic leukemia
por: Park, Hye-Jin, et al.
Publicado: (2016)

Pancreatic Extraskeletal Osteosarcoma Metastasizing to the Scalp
por: Kim, Young Jae, et al.
Publicado: (2018)

Evaluation of zoledronate for the treatment of canine stage III osteosarcoma: A phase II study
por: Smith, Ashley A., et al.
Publicado: (2022)

Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma
por: Horie, N, et al.
Publicado: (2007)

Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization
por: Kim, Jin Ho, et al.
Publicado: (2016)

Preliminary Radiogenomic Evidence for the Prediction of Metastasis and Chemotherapy Response in Pediatric Patients with Osteosarcoma Using (18)F-FDG PET/CT, EZRIN, and KI67
por: Kim, Byung-Chul, et al.
Publicado: (2021)

Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma
por: Byrum, M.L., et al.
Publicado: (2016)

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer
por: Jang, Na Young, et al.
Publicado: (2015)

Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer
por: Park, Jung Hee, et al.
Publicado: (2017)

Use of zoledronic acid in the treatment of Paget’s disease
por: Seton, Margaret, et al.
Publicado: (2007)

Role of zoledronic acid in the prevention and treatment of osteoporosis
por: Räkel, Agnès, et al.
Publicado: (2011)

Zoledronic acid infusion for prevention and treatment of osteoporosis
por: Sunyecz, John A
Publicado: (2010)

Treatment outcomes of stereotactic body radiation therapy for primary and metastatic sarcoma of the spine
por: Kim, Eunji, et al.
Publicado: (2023)

Correction: Treatment outcomes of stereotactic body radiation therapy for primary and metastatic sarcoma of the spine
por: Kim, Eunji, et al.
Publicado: (2023)

Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
por: Park, Jung-Wee
Publicado: (2021)

Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy
por: Wu, Chia-Chieh, et al.
Publicado: (2016)

A Patient-Derived Organoid-Based Radiosensitivity Model for the Prediction of Radiation Responses in Patients with Rectal Cancer
por: Park, Misun, et al.
Publicado: (2021)

Extraskeletal Osteosarcoma Arising from the Pleura
por: Lee, Chee-Hoon, et al.
Publicado: (2014)

The anti-tumour effects of zoledronic acid
por: Zekri, Jamal, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u74am8g5rscbifbsjt5sgn7a7f